7 recruiting, 2 active not recruiting. 5 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 4, Active not recruiting 1 |
| Phase 1 | 4 | Active not recruiting 2, Recruiting 2 |
| Phase 3 | 2 | Recruiting 2 |
Follow ADARx Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chinese Adults With Kidney Disease ADX-038, Telitacicept - Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G) | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 30 | 2026-05-21 | 2026-09-03 |
| Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) ADX-324 Dose Level 1, ADX-324 Dose Level 2 - Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1 | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2026-04-02 | 2026-09-04 |
| Phase 2 Study of ADX-038 in Participants With Geographic Atrophy ADX-038, Placebo - Geographic Atrophy Secondary to Age-related Macular Degeneration | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 240 | 2025-11-10 | 2026-09-03 |
| STOP-HAE: A Phase 3 Study of ADX-324 in HAE ADX-324, Placebo - Hereditary Angioedema, HAE | Phase 3 | Recruiting | ADARx Pharmaceuticals, Inc. | 90 | 2025-08-28 | 2026-09-10 |
| Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease ADX-038 Dose Level 2, ADX-038 Dose Level 1 - IgAN, C3G | Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 45 | 2025-08-28 | 2026-10-20 |
| Phase 1 Study of ADX-626 in Healthy Participants ADX-626, Placebo - Healthy Adult Participants | Phase 1 | Recruiting | ADARx Pharmaceuticals, Inc. | 44 | 2025-08-12 | 2026-09-10 |
| Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension ADX-850, Placebo - Hypertension, Hypertension,Essential | Phase 1 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 28 | 2024-03-21 | 2026-09-03 |
| Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients ADX-038, Placebo - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 1 / Phase 2 | Recruiting | ADARx Pharmaceuticals, Inc. | 50 | 2023-08-07 | 2026-06-16 |
| Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients ADX-324, Placebo - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 53 | 2022-12-14 | 2026-06-16 |
Angioedemas, Hereditary (3) · Glomerulonephritis, IGA (2) · Essential Hypertension (1) · Glomerulonephritis, Membranoproliferative (1) · Hemoglobinuria, Paroxysmal (1) · Hypertension (1)
RNA, Small Interfering (5) · Sodium Chloride (3) · telitacicept (1)
Australia (7) · United Kingdom (6) · Spain (4) · United States (4) · Austria (3) · Canada (3) · China (3) · Czechia (3) · Germany (3) · Hong Kong (3) · Hungary (3) · Italy (3) · Taiwan (3) · Argentina (2) · Belgium (2)
Lauge Farnaes, MD (3) · Arezoo Mirad, MD (2) · Arezoo Mirad (1) · Wendy Murahashi (1)